These chemicals have nearly no history of human use prior to 2010 when they first became available online, and very little is known about this group of compounds. They should only be used with extreme caution. It's recommended to not take more than 1.5 mg of any substance of the NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. family, as there have been multiple deaths from people just taking 2-3 blotters.
Effects have been reported to vary wildly between people (example: person A gets a 4-hour body high with barely any visual aspects, while person B gets a >12 hour DOB-like trip with an intense visual aspect). Drugs affect all users differently, but this unusually wide range of reported effects is down, in part, to users being unable to accurately distinguish between members of the NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. series, and misrepresentation of doses - a single tab regularly yields between 500ug and 2000ug of the substance.
NBOMesN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. were initially thought to be orallyRoute of administration in which the subject swallows a substance. inactive, meaning they wouldn't work if swallowed. However, this is not the case for all NBOMesN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. per se; certain NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. salts do have an observed oral bioavailabilityThe fraction of an administered dose that is absorbed into a living system., with little known about the oral bioavailabilityThe fraction of an administered dose that is absorbed into a living system. of NBOMesN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. in their freebase form. Therefore, when a substance might be an NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines., discard the blotter entirely rather than swallowing it, if you do not wish to risk being under the influence of an NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines.. Oral administrationRoute of administration in which the subject swallows a substance. is relatively uncommon and thus undocumented, presumably as a result of the existing confusion about the oral availability of NBOMesN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines.. Sublingual administrationRoute of administration in which the subject places a substance under the tongue. is the most common, but buccal administrationRoute of administration in which the subject places a substance against their gums or other oral mucosa. is recommended if you wish to avoid the generally bitter taste of NBOMesN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines..
| Light | 200-500 μg |
| Common | 500-1500 μg |
| Strong | 1500+ μg |
| Light | 100-400 μg |
| Common | 400-700 μg |
| Strong | 700+ μg+ |
| Light | 100-300 μg |
| Common | 300-800 μg |
| Strong | 800+ μg |
| Light | 100-300 μg |
| Common | 300-500 μg |
| Strong | 500-700+ μg |
| Light | 50-200 μg |
| Common | 200-350 μg |
| Strong | 350-500+ μg |
| Onset | 15-45 minutes |
| Total | 4-11 hours |
| Onset | 0-10 minutes |
| Total | 3-8 hours |
Likelihood of negative side effects increases with higher doses.
NBOMesN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. are considered less safe than many psychedelics due their heavy physical effects on the body, and as recreational dosages tend to overlap with what have been fatal dosages. Even so, many reports of death by an NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. chemical involve mislabeling of the drug, sometimes by the distributor (example: someone insufflates 20mg of 25I-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. because he/she thought it was 2C-I). Mislabeling or misweighing can easily lead to extrememely dangerous, sometimes lethal, situations. Administration of an NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. in its powder form (either insufflated or otherwise) is strongly discouraged, as the potency is far greater than the accuracy of most scales.
Furthermore, due to the physical strain the drug causes one should not use it if there are any pre-existing heart conditions.
See Psychedelic Harm Reduction for general information.
The NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. series of psychoactives became controlled in the Russian Federation starting October, 2011.[1]
The UK Home Office announced that 25I-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. would be made a class A drug on 10th June 2014 alongside every other N-benzyl phenethylamines.[2]
25i-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines., 25b-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines., and 25c-NBOMeN-Benzyl-Ortho-Methoxy derivatives of psychedelic phenethylamines. were emergency scheduled by the DEA on Novemeber 15, 2013[3]
25B-NBOMe
25C-NBOMe
25I-NBOMe